# Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06293651/  
OnCo record `nct06293651` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Dong-A ST Co., Ltd., now recruiting.

## Summary

Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06293651 by Dong-A ST Co., Ltd., with 125 participants planned, started 2024-04-18 and due to reach its primary completion in 2026-01. Interventions recorded: DA-4505 and DA-4505 + Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06293651
- Phase: 1/2
- Setting: an Open-Label, Phase 1/2a, First-in-Human Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
- Sponsor: Dong-A ST Co., Ltd.
- Enrolled: 125

## Sources

- ClinicalTrials.gov NCT06293651: https://clinicaltrials.gov/study/NCT06293651

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Dong-A ST](https://onco.cc/companies/dong-a-st/)

---
JSON: https://onco.cc/api/v1/entities/nct06293651.json